# Fresenius Medical Care

> Fresenius Medical Care is a VC fund backing Medical and Health Care. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bad Homburg, Germany
- Total investments: 19
- Last investment: Sep 2024
- Lead investor: 32%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/freseniusmedicalcare
- X (Twitter): https://twitter.com/fmc_ag
- Website: https://www.freseniusmedicalcare.com
- Facebook: https://www.facebook.com/pg/FreseniusMedicalCare.Corporate/

Fresenius Medical Care is a provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. It has a network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa. It offers specialty pharmacy andlaboratory services and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.The company was founded in 1996 and is headquartered in Bad Homburg, Frankfurt.

## Contacts

5 contacts available for Fresenius Medical Care. Shizune tracks 18 team members at Fresenius Medical Care. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/fresenius-medical-care?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 7 | 37% |
| Health Care | 6 | 32% |
| Biotechnology | 6 | 32% |
| Medical Device | 4 | 21% |
| Genetics | 2 | 11% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 7 | 37% |
| Series A | 3 | 16% |
| Series C | 2 | 11% |
| Corporate Round | 2 | 11% |
| Post-IPO Equity | 2 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 47% |
| Israel | 1 | 5% |
| Switzerland | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andreas Wüpper | Director Investments Europe | 2 | https://shizune.co/investors/profile/andreas-wupper |
| Brian Silva | Senior Vice President, Human Resources and Administration | 0 | https://shizune.co/investors/profile/brian-silva |
| Carsten Heil | VP Engineering Solutions | 0 | https://shizune.co/investors/profile/carsten-heil |
| Christian Kuhn | User Experience Lead | 0 | https://shizune.co/investors/profile/christian-kuhn |
| Deborah Anne Harvey | Senior Vice President, Operations President, East Division | 0 | https://shizune.co/investors/profile/deborah-anne-harvey |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M | Series D | Sep 04, 2024 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M | Series C | May 07, 2024 |  |
| VR Medical | VR Medical, a US based company, was established in 2009 to provide medical device companies, and distributors, a new and more effective low-cost, high-quality manufacturing resource.They’re focused on serving the needs of medical device companies by providing a single-sourced solution for new product development, out sourcing, contractmanufacturing, and secure product distribution within China. |  | Corporate Round | Dec 08, 2023 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $27.6M | Series C | Nov 02, 2023 |  |
| Memo Therapeutics | Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $24.9M | Series B | Feb 16, 2022 |  |
| SafeRide Health | SafeRide Health is a healthcare technology platform developer that aims to simplify medical transportation, expedite care coordination, and improve patient outcomes. The company's platform enables health plans to manage its members with greater intelligence and control, delivering end-to-end data transparency while improving patientexperience, population health, and programs, and giving patented fleet management solutions to the healthcare industry. |  | Series B | Nov 08, 2021 |  |
| Humacyte | Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate therisk of rejection; and vascular grafts. | $175M | Post-IPO Equity | Aug 27, 2021 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $125M | Series C | Mar 02, 2021 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $100M | Series B | Nov 07, 2019 |  |
| BioIntelliSense | BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM) and Health Screening. Our medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs, physiological biometrics and symptomatic events through an effortless patient experience.The FDA-cleared BioSticker™ and BioButton® devices make remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians will now have access to high-resolution patient trending and reporting to enable medical grade care from in the hospital to the home, and all points in-between. | $25M | Series A | Jul 09, 2019 |  |

10 of 19 investments shown.

## Co-investors
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 5 deals together
- [Swisscanto Private Equity](https://shizune.co/investors/profile/swisscanto-invest) — VC Fund, 4 deals together
- [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners) — VC Fund, 4 deals together
- [GF Group Holding](https://shizune.co/investors/profile/gf-group-holding) — VC Fund, 3 deals together
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 3 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Fresenius Medical Care invest in?

Fresenius Medical Care invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Fresenius Medical Care?

Public channels for Fresenius Medical Care include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Fresenius Medical Care?

The team at Fresenius Medical Care includes Andreas Wüpper (Director Investments Europe), Brian Silva (Senior Vice President, Human Resources and Administration) and Carsten Heil (VP Engineering Solutions), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co